argenyx business update

argenx (ARGX) reported strong Q1 2025 financial results with $790 million in global product net sales, representing 99% year-over-year growth. The company achieved profitability with $169.5 million in net income ($2.78 per share) compared to a loss in Q1 2024. Key developments include the launch of VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany, and a positive CHMP opinion for VYVGART-SC in EU for CIDP. The company maintains its 'Vision 2030' strategy to reach 50,000 patients across 10 labeled indications. Operating expenses increased to $668.4 million, with R&D expenses at $309 million and SG&A at $276.2 million. The company reaffirmed its financial guidance of approximately $2.5 billion in combined SG&A and R&D expenses for 2025.

https://www.stocktitan.net/news/ARGX/argenx-reports-first-quarter-2025-financial-results-and-provides-zj8c6zjcqpcy.html